SEC Filing · 4
Surrozen, Inc.
SRZNNASDAQEQUITYCurrent
SEC Filing
Company context
Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling in combination with other key disease pathways. Our approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes in some of the most pressing unmet medical needs in ocular diseases. For more information, visit www.surrozen.com.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗